Frequency of erosive lesion of the mucraful stomach in patients with cardiovascular diseases in ambulatory practice

The aim of the research: To study the incidence of erosive lesions of the gastric mucosa in patients with cardiovascular diseases receiving ASA drugs and under the supervision of outpatient physicians. Material and methods: The analysis of outpatient cards of 2215 patients of the city polyclinic Moscow, who underwent an endoscopic examination of the upper gastrointestinal organs and treatment from August 2017, was performed until April 2018. All patients underwent esophagogastroduodenoscopy using Olympus GIF-Q150 and Olympus GIF-XQ30. The results of the study: The study shows that the number of patients with erosive lesions of the mucosa of ARV and receiving ASA drugs is several times greater than patients with erosive lesions of the mucosa of the non-taking ASA. These results confirm the effect of the disaggregant therapy of cardiovascular diseases on the occurrence of erosive lesions. Conclusion: More than 25% of patients with cardiovascular diseases who are prescribed therapy for the underlying disease have erosive lesions of the gastric mucosa. These patients simultaneously need a preventive intake of drugs that protect the mucous membrane.